オプションチェーンは、Mereo BioPharma Groupの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Mereo BioPharma Groupの市場センチメントを評価します。.

Mereo BioPharma Group (NASDAQ:MREO) 株価情報, オプションチェーン

Mereo BioPharma Group

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

News

Pre-Market Outlook

Markets

Movers

AYRO

CLDI

CLNN

GDHG

GOOGL

MREO

OBLG

ORCL

PETS

PIXY

SRFM

THMO

TNXP

WLGS

オラクル・コーポレーション (NYSE:ORCL) の株価は、同社が第4四半期決算を発表した後、本日のプレマーケット取引で急騰しました。オラクルは自社の2021年4月～6月期決算において、予想を下回る決算を発表しました。同社は、アルファベット（Alphabet Inc）（NASDAQ:GOOGL）（NASDAQ:GOOG）のGoogle Cloudと提携することも発表しました。

オラクルの株価9%上昇の理由

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group PLC

Mereo Biopharma Group Plc (MREO) has shared an announcement. Mereo BioPharma Group plc has partnered with key underwriters for a public offering of...

Mereo BioPharma's Public Offering and Strategic Underwriter Partnership

Mereo BioPharma: Positioned For Potential Breakthroughs

HRTS: Generating Alpha In Obesity Treatment

Mereo BioPharma Group GAAP EPS of -$0.02

Analyst Gil Blum of Needham maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report), retaining the price target of $7.00. Gil...

Mereo Biopharma Group: A Strong Buy on Promising Clinical Data and Robust Financials

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on MREO stock, giving a Buy rating on August 13. Joseph Schwartz has g...

Strong Buy Rating for Mereo Biopharma Amidst Promising Drug Program Developments

New additions to Roth MKM's ADR portfolio for September

Mereo BioPharma - Lazarus-Like Recovery Impresses, But Lack Of Clarity On Potential Approval Timelines

"The Phase 3 program for setrusumab, led by our partners at Ultragenyx, continues to progress according to plan and we look forward to reporting th...

Mereo BioPharma reports Q3 EPS (2c), consensus (2c)

Analyst Gil Blum from Needham maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report) and keeping the price target at $7.00. ...

Mereo Biopharma Group: Anticipated Positive Developments and Strong Financial Position Justify Buy Rating

AMGN

ARGT

ARGX

ATAT

BGNE

BWAY

CNTA

CRESY

CYTK

GGAL

HRTS

LOMA

MOMO

QFIN

RARE

SONY

VNET

VRNA

Press Releases

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Earnings

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

Financing

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Abivax

Alector

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

AnaptysBio

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Astria Therapeutics

Aura Biosciences

Celcuity

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Emergent BioSolutions

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Humacyte

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Opthea Limited - American Depositary Shares

Opthea

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Regenxbio

Sana Biotechnology

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Stoke Therapeutics

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tourmaline Bio

Y-mAbs Therapeutics

Needham

Cantor Fitzgerald

Leerink Partners

Baird

SVB Leerink

Comments

Mereo BioPharma Group

Mereo BioPharma Group (MREO) オプション

Mereo BioPharma Group (NASDAQ:MREO) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル